Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Pharmos successfully completes phase II head trauma study

Oct. 13, 1998

5-HT2C agonist shows potential for treating OCD and depression

Oct. 13, 1998

Lundbeck develops new antipsychotic agents acting on D1 receptors

Oct. 13, 1998

Novel central 5-HT1A receptor agonists characterized in binding and animal studies

Oct. 13, 1998

Celgene initiates pivotal trials with d-MPH

Oct. 9, 1998

Creative BioMolecules receives NIH grant for Parkinson's disease research

Oct. 9, 1998

Elan obtains North American marketing rights for frovatriptan

Oct. 9, 1998

SB receives clearance to market Seroxat for important new indication in the U.K.

Oct. 9, 1998

Novartis submits NDA for Trileptal

Oct. 9, 1998

NeoTherapeutics completes enrollment in phase II trial of Neotrofin

Oct. 9, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...